Cape Fear BioCapital

Profile

Cape Fear BioCapital is a venture capital firm based in Research Triangle Park, North Carolina, founded in late 2024. The firm is led by General Partners Ed Field, Jimmy Melton, and Dave Ousterout, who all have extensive backgrounds in biotechnology and company leadership. Cape Fear BioCapital differentiates itself through its deep operational experience and hands-on company-building approach, focusing on transforming scientific insights into viable therapeutic solutions.

The firm primarily invests in early-stage therapeutics companies in North Carolina, emphasizing pre-seed to seed stage opportunities. They back companies with validated biological mechanisms, novel modalities, and robust therapeutic platforms, often those associated with local research institutions like Duke, UNC, and NC State. Cape Fear BioCapital writes first checks and invests alongside strategic partners, including Parexel, to cultivate seed-ready innovations in life sciences.

Notable investments from Cape Fear BioCapital's portfolio include Thoracic Innovations, a surgical tool developer; Ten63 Therapeutics, an AI-driven drug discovery company; Incyclix Bio, an oncology firm creating CDK2 inhibitors; iOrganBio, focused on AI-driven cell manufacturing; EnFuego Therapeutics, working on an RNAi platform for cancer; and Eldec Pharmaceuticals, a developer of respiratory peptides.